Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024
Fractyl Health, Inc. (GUTS)
Company Research
Source: GlobeNewswire
Single Revita procedure led to sustained, clinically meaningful weight loss in majority of patients with Type 2 Diabetes REMAIN-1 weight maintenance pivotal study on-track to report mid-point data analysis in Q2 2025 Company will report weight maintenance data after discontinuation of GLP-1 drugs in open-label REVEAL-1 cohort in Q4 2024 BURLINGTON, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), presented the poster, “Duodenal Mucosal Resurfacing (DMR) Durably Maintains Weight Loss in Metabolic Disease,” on Sunday, November 3, 2024, during The Obesity Society’s Annual Meeting at ObesityWeek 2024 in San Antonio, Texas. The poster showcased compelling results of a pooled data analysis from five clinical studies, n=118, where participants were followed for 48 weeks post-Revita procedu
Show less
Read more
Impact Snapshot
Event Time:
GUTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GUTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GUTS alerts
High impacting Fractyl Health, Inc. news events
Weekly update
A roundup of the hottest topics
GUTS
News
- Fractyl Health Third Quarter 2024 Earnings: US$0.48 loss per share (vs US$9.61 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire
- Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024GlobeNewswire
- Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024GlobeNewswire
GUTS
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 4
- 11/13/24 - Form 4
- GUTS's page on the SEC website